Ra Pharmaceuticals Inc
(RARX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 81,059 | 95,057 | 109,122 | 70,381 | 84,091 |
| TOTAL | $83,561 | $98,149 | $110,858 | $72,877 | $85,214 |
| Non-Current Assets | |||||
| PPE Net | 5,394 | 5,709 | 5,621 | 5,606 | 5,967 |
| Intangibles | 330 | 347 | 363 | 380 | 396 |
| Other Non-Current Assets | 1,334 | 1,334 | 1,334 | 1,334 | 1,334 |
| TOTAL | $7,058 | $7,390 | $7,318 | $7,320 | $7,697 |
| Total Assets | $90,619 | $105,539 | $118,176 | $80,197 | $92,911 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,899 | 3,901 | 2,571 | 4,348 | 3,377 |
| Accrued Expenses | 4,749 | 4,092 | 4,194 | 3,937 | 3,994 |
| TOTAL | $8,117 | $8,453 | $7,215 | $8,614 | $7,803 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 469 | 460 | 450 | 329 | 432 |
| TOTAL | $2,043 | $2,166 | $2,286 | $2,399 | $2,531 |
| Total Liabilities | $10,160 | $10,619 | $9,501 | $11,013 | $10,334 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,398 | 32,340 | 32,287 | 32,287 | 22,627 |
| Common Shares | 32 | 32 | 32 | 23 | 23 |
| Retained earnings | -171,961 | -155,458 | -139,712 | -123,214 | -108,073 |
| TOTAL | $80,459 | $94,920 | $108,675 | $69,184 | $82,577 |
| Total Liabilities And Equity | $90,619 | $105,539 | $118,176 | $80,197 | $92,911 |